Given that inhibition of acetylcholinesterase is widely considered a therapeutic target for ameliorating AD [192], helicusin A is seen as a promising lead compound to develop a potential novel pharmaceutical regime against AD. The gene discussed is ACHE; the disease is Alzheimer disease.